Get the Stockscreener App
1.08
3.57%
-0.04
Radiopharm Theranostics Ltd Adr stock is traded at $1.08, with a volume of 62,856.
It is down -3.57% in the last 24 hours and down -28.95% over the past month.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
62,856
Relative Volume:
1.05
Market Cap:
$15.76M
Revenue:
$2.34M
Net Income/Loss:
$-30.37M
P/E Ratio:
-0.367
EPS:
-2.9424
Net Cash Flow:
$-23.42M
1W Performance:
-2.70%
1M Performance:
-28.95%
6M Performance:
-76.77%
1Y Performance:
-84.81%
1-Day Range:
$1.011
$1.15
1-Week Range:
$1.01
$1.33
52-Week Range:
$1.00
$16.25
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Name
Radiopharm Theranostics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare RADX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
1.08 | 15.76M | 2.34M | -30.37M | -23.42M | -2.9424 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-26 | Initiated | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Stock (RADX) Latest News
Radiopharm Theranostics Files 2026 Annual Report as Nasdaq-Listed Foreign Issuer - TipRanks
Radiopharm Theranostics Files Annual Form 20-F Report with SEC for Fiscal Year Ended 30 June 2026 - Kalkine
Radiopharm Theranostics Shareholders Back Full Suite of Capital Resolutions - TipRanks
OPTH Stock Price, Quote & News - Syfe
Radiopharm Theranostics Reports Promising Phase 1 Imaging Results for RAD301 in Pancreatic Cancer (NASDAQ: RADX) - kalkinemedia.com
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
RADX - Finviz
TRIB Stock Price, Quote & News - Syfe
Radiopharm Theranostics Posts Deeper FY26 Loss as R&D Spend Jumps and Cash Reserves Fall - TipRanks
Radiopharm Theranostics rebuilds its balance sheet as cancer pipeline delivers early trial wins - Kalkine
Radiopharm Theranostics Limited American Depositary Shares (NASDAQ: RADX) Stock Price, News & Analysis - kalkine.ca
Radiopharm Theranostics (RADX) seeks shareholder approval for placements, SPP and new warrants - Stock Titan
Radiopharm Theranostics Limited American Depositary Shares (NASDAQ: RADX) Stock Price, News & Analysis - Kalkine
Radiopharm Theranostics Applies to Quote 408.8 Million Shares from Tranche 1 Australian Placement - Kalkine
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Call Dominated - careplusvn.com
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Stock Analysis - vinanet.vn
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Dealer Gamma - dars.gov.et
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Quality Factor - dars.gov.et
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Composite Profile - dars.gov.et
Radiopharm Theranostics Reports Business Update - Sahm
Regal Partners' Voting Power in Radiopharm Theranostics Falls to 7.33% After Share Issue - Kalkine
Radiopharm Theranostics Secures Multimillion-Dollar Financings to Advance Oncology Radiopharmaceutical Pipeline - TipRanks
Radiopharm stock tumbles 21% on dilutive capital raise By Investing.com - Investing.com Nigeria
Radiopharm stock tumbles 21% on dilutive capital raise By Investing.com - Investing.com South Africa
Radiopharm Theranostics Raises A$12.5 Million in Institutional Capital as RAD101 Phase 3 Trial Nears Commencement - Kalkine
Radiopharm Theranostics Announces Concurrent US$4.1 Million - GlobeNewswire
Radiopharm stock tumbles 21% on dilutive capital raise - Investing.com
RAD:ASX AnnouncementRAD completes A$12.5 M placement and launches A$6 M SPP24 Jul 2026 - Market Index
Radiopharm Theranostics raises US$4.1M via US o... - Pluang
Radiopharm Theranostics (ASX:RAD) Raises AUD 12.5 Million to Advance Phase 3 Cancer Therapy Program - kalkinemedia.com
Radiopharm raises $8.8 million in U.S. and Australian placements - Investing.com
Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials - smallcaps.com.au
Radiopharm Theranostics (RADX) Holds Steady Near Support Amid Light TradingOBV Breakout - Vinanet
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Radiopharm Theranostics Limited Financial Disclosures & SEC Filings - TradingView
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
Radiopharm Theranostics (RADX) Gains 1.73% as Stock Hovers Above Key Support at $4.13Percent Below MA - po-news-eg.net
Radiopharm Theranostics stock initiated with buy rating at H.C. Wainwright - Investing.com
RADX - Finviz
Radiopharm Theranostics (RADX) Institutional Ownership 2026 - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Radiopharm Theranostics Ltd Adr Stock (RADX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):